Announcing a Drop in the Price of the 4Kscore™ Test

We often hear from patients and physicians alike interested in learning more about the 4Kscore test as well as the associated cost. We have always worked to offer the 4Kscore tests at a reasonable price. With our Patient Health Advocacy Program, we are committed to increasing access to the 4Kscore for patients who do not have health insurance. Through these efforts, we have been successful in making comprehensive testing available to an expanding network of patients.

The New Price of the 4Kscore Test

We are very excited to announce that the 4Kscore test is now more affordable. The price has been reduced from $1900 to $595, making testing more accessible to men at an increased risk of having aggressive prostate cancer. If you would like to discuss your specific situation, and our self-pay and payment plan options, please call our specialized billing hotline at 855-4KBILLING (855-452-4554) between the hours of 9am and 9pm EST, Monday-Friday.

The Cost of Unnecessary Biopsies

As we recently discussed in a post on the topic, the cost associated with unnecessary biopsies preformed in the United States annually is staggering. Not only is the 4Kscore aiding in the biopsy decision making process, it can help to reduce the number of unnecessary biopsies performed on an annual basis.

In helping patients, along with their doctors, make informed decisions about prostate biopsies, the 4Kscore is dramatically reducing the pain and cost associated with unnecessary procedures.1 In reducing the cost of the 4Kscore, we aim to make an even greater impact in the fight against prostate cancer.

Learn More About the 4Kscore Test

Whether you are a patient or a physician, we encourage you to contact us today. Learn more about the benefits of the 4Kscore. Find a laboratory in your area or begin offering the 4Kscore in your practice. Together we can make a difference!

 

  1. Voigt, J. D., MPH, MBA, Dong, Y., PhD, Linder, V., PhD, & Zappala, S., MD. (2017). Use of the 4Kscore Test to Predict the Risk of Aggressive Prostate Cancer Prior to Prostate Biopsy: Overall Cost Savings and Improved Quality of Care to the US Healthcare System. Reviews in Urology, 19(1), 1-10.